Doceree wants pharma ads to follow the prescription

A prescription has an odd double life. To the pharmaceutical marketer, it can be the finish line: the physician has made a decision. To the patient, it is an instruction with several obstacles still attached. There may be a price to discover, an insurance approval to secure, a pharmacy to visit. The advertising dashboard and the medicine cabinet occupy different worlds. Doceree is trying to build a business across the distance between them.

That ambition explains why an advertising company now has products for publishers, electronic health records, virtual brand representatives and patient affordability. It also supplies a useful test. If Doceree’s system merely delivers more messages, it risks adding to the physician’s burden. If it helps deliver useful information at a relevant decision, and can measure what follows, the proposition becomes considerably more interesting.

The door closed. The browser stayed open.

Harshit Jain came to the problem through medicine and healthcare advertising. After practising as a physician, he worked at McCann Health across several markets. Doceree’s early story also includes co-founder Daleep Manhas, another healthcare marketing veteran. Contemporary reporting dates the founding to 2019; the platform’s launch came in 2020. The distinction matters less than the timing.

For an industry accustomed to sales representatives visiting physicians, lockdown was a brutal experiment. Meetings disappeared. The need to communicate did not. Jain has described pre-pandemic reluctance to adopt digital physician marketing and the sudden change when face-to-face contact became difficult. The early obstacle was acceptance: pharma already had a familiar way to reach doctors, and familiarity is a formidable competitor.

Doceree assembled physician-focused digital platforms into a network. A brand could buy access through one interface instead of negotiating every professional site separately. The company announced a $1 million seed round in May 2020. In January 2021 it launched programmatic point-of-care messaging, bringing the proposition closer to the clinical workflow and naming OptimizeRx’s EHR and electronic-prescribing network among its connections.

“Our mission is to streamline Physician marketing”Harshit Jain · January 2021

This was a change in distribution, with a rather good sense of where its audience lived. A physician reading a specialist journal and a physician writing a prescription are the same person doing different jobs. The context changes what information might be useful. Doceree’s bet was that an advertising system should understand that distinction.

A doctor is an audience. A decision is a moment.

The company’s identity technology, Espyian, is designed to recognize verified healthcare professionals across its network. Its Clinical Intent Signals add context from professional activity. Identity helps answer who should receive the message; clinical context helps decide when and where. The distinction is simple enough to explain, though assembling the integrations behind it is a less elegant afternoon’s work.

Spark, launched at HIMSS in 2024, operates in the point-of-care environment. The current EHR offering describes triggers based on clinical events, including diagnosis, procedure and drug codes. Its modules cover affordability at prescribing, therapy education and clinical-trial matching. The platform partner controls how information appears in the physician’s workflow.

Take the company’s affordability use case. A savings option shown while a prescription is being written could address a practical obstacle before the patient leaves. That is a different job from showing an awareness ad beside a medical article. Doceree’s “nudges” language describes brief, context-sensitive messages intended to fit the moment without obstructing the work. The value depends on whether that intention survives implementation.

Doceree reports more than 185 EHR and health-system integrations and 2,000 medical publisher integrations. Those numbers describe distribution relationships. They do not mean every physician can be reached in every setting, or that every brand can activate every channel. Geography, eligibility, content approval and the partner’s own rules still matter.

The publisher has something worth selling

The other side of this business is supply. Medical publishers attract a professional audience that pharmaceutical advertisers want to reach. AdManager gives those publishers healthcare-specific inventory management, physician targeting and reporting. Doceree names Cogora and Taylor & Francis among its publisher partners.

The economics are recognizable: advertisers pay to reach an audience, and publishers need revenue to support the environment that attracted it. Doceree sits between the two with identity and delivery technology. Its careers site describes a customer base of more than 115 pharmaceutical brands and 30 media agencies. The company also offers self-service and managed-service campaign environments.

The Publisher AI Suite extends the proposition to on-site editorial assistants, bot protection and content licensing. It is an attempt to address publishers’ changing distribution problem as AI interfaces become another place readers encounter information. Selling advertising and protecting editorial assets are different tasks, but the publisher now has reason to discuss both with the same vendor.

Doceree’s expansion has also used local partners. Hello Health Group announced a Southeast Asia partnership in 2023. The Ward Marketing Group partnership followed in Australia in October 2024. A network can supply technology; local expertise helps determine how a healthcare campaign should actually behave in a particular market.

The pharmacy moves into the picture

The newer product family follows the message beyond the media buy. RepTwin is an AI-powered virtual brand representative intended to extend engagement outside the field team’s visits. Co-pay.com addresses savings delivery, consent-based enrollment and prior authorization. Daily Command brings intelligence, activation and measurement into a marketer’s workspace.

These products reveal the shift in Doceree’s argument. Finding the doctor was the beginning. The company now wants to link awareness, prescribing and access. An engaged physician cannot, by enthusiasm alone, remove an unaffordable bill or an unfinished authorization. The clinical decision and the patient’s ability to act on it have to meet somewhere.

There are also distinct data responsibilities. Doceree describes advertising audiences as de-identified and linked at the segment level. Its affordability service describes patient information used with consent for enrollment and support. Those uses should not be collapsed into one cheerful claim about “data.” They serve different purposes and require different permissions.

Its public site illustrates the measurement pitch with an oncology campaign reporting a 25% lift in total prescriptions, 15% in new prescriptions and 12% in new prescribers. These are company-reported results from one study, not a forecast for the next buyer. Prescription growth also differs from improved health. The former is a commercial measure; the latter requires evidence of its own.

Seventy-five people rearrange the workday

Daily Command’s development provides a more concrete lesson than most launch slogans. At the May 7, 2026 Health Decode Makers Summit in New York, Doceree put unresolved product decisions in front of 75 senior industry participants. Its account describes table discussions, a live forum and three voted changes incorporated into the evening demonstration.

The useful detail is the unfinished decision. Asking customers to applaud a completed product is easy. Giving them a choice while the choice can still alter the product is more valuable. Doceree followed the summit with a five-partner beta, including Avalere Health, and lists Daily Command as publicly live from July 14, 2026.

The company’s careers page describes small teams, substantial ownership and decisions recorded in writing. That is the employer’s account of its culture. The summit at least supplies a visible example of the preference: people close to the problem were invited to change the work.

The cost of connecting the pieces

Building this network has required capital. An $11 million Series A in 2022 preceded the $35 million Series B announced in September 2023, led by Creaegis with Eight Roads Ventures and F-Prime Capital participating. The stated uses included product development, technology, international expansion and hiring. These are financing amounts, not the price of a campaign or a tally of what building the system ultimately cost.

For a buyer, the sensible calculation starts with the job: specialist awareness, point-of-care education, access support or measurable prescription change. Doceree’s marketplace support guidance says partner offerings are charged when used in a live campaign. A useful commercial discussion therefore connects the media budget and selected services to a defined result, rather than treating the product catalogue as a shopping challenge.

There are credible alternatives, including PulsePoint, DeepIntent and OptimizeRx, as well as direct publisher buying. Doceree’s distinctive pitch is the combination of professional identity, publisher reach, clinical integrations and downstream measurement. The buyer’s question is whether that combination improves a particular campaign enough to justify its cost and integration work.

The lesson travels beyond pharma. Find the place where the customer makes a decision. Supply information that belongs there. Decide in advance what later action would count as success. The approach loses force when the relevant workflow is inaccessible, the message is unhelpful or the outcome cannot be measured credibly. More precise targeting cannot rescue a poor proposition.

Doceree began by opening another route to physicians. Its current ambition is to make the route continue after the prescription. That is a more demanding business to build, and a better question to ask of an advertising report: what happened when the patient reached the counter?